American College of Cardiology

JANUARY 15, 2025

Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.

Preserved Ejection Fraction 43

Preserved Ejection Fraction Heart Failure Obesity Diabetes 43

Circulation: Heart Failure

JANUARY 28, 2025

BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. The generated organoids were then subjected to HFpEF-associated, comorbidity-inspired conditions, such as hypertension, diabetes, and obesity-related inflammation. versus 2.330.46

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Diabetes 40

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

European Journal of Heart Failure

MARCH 19, 2025

Abstract Aims Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Stenosis Aortic 40

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Investigators randomized 616 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=310) or placebo (n=306). April 6, 2024.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. The study analyzed the effects of semaglutide 2.4

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Journal of the American Heart Association

JANUARY 23, 2025

BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Journal of the American Heart Association, Ahead of Print. Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.

Heart Failure 45

Heart Failure Preserved Ejection Fraction Obesity Outcomes 45

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). New developments in continuous glucose monitors (CGMs) have also been transformative.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59